Subtype
Prostate Neoplasm
CI-CAN-00003778Explore in graph →
Non-malignant1,453 active trials24 approved drugs58 evidence items
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00003778Explore in graph →
Clinical trials
6,544 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00430235 | A Study of BAY 43-9006 in Combination With Bicalutamide in Patients With Chemo-Naïve Hormone Refractory Prostate Cancer | completed | Phase 2 | 39 | British Columbia Cancer AgencyOTHER | 1 | Aug 5, 2010 | clinicaltrials |
| NCT00193193 | Weekly Paclitaxel, Low-Dose Estramustine, and Carboplatin in the Treatment of Hormone Refractory Prostate Carcinoma | completed | Phase 2 | 100 | SCRI Development Innovations, LLCOTHER | 0 | Aug 4, 2010 |
| NCT00193232 | Weekly Docetaxel and Bortezomib in the Treatment of Advanced Hormone-Refractory Prostate Cancer | completed | Phase 2 | 50 | SCRI Development Innovations, LLCOTHER | 0 | Jul 28, 2010 | clinicaltrials |
| NCT00855647 | Hypofractionated Radiotherapy for Localized Prostate Cancer (With CyberKnife or With IMRT) | completed | Phase 2 | 99,999 | Stanford UniversityOTHER | 1 | Jun 3, 2010 | clinicaltrials |
| NCT00305929 | Study of WST09 in Prostate Cancer After Radiation: Repeat Procedure | completed | Phase 2 | 8 | STEBA FranceINDUSTRY | 1 | Jun 2, 2010 | clinicaltrials |
| NCT00312442 | Phase II/III Study of WST09 in Prostate Cancer After Radiation Therapy | terminated | Phase 2 / Phase 3 | 16 | STEBA FranceINDUSTRY | 1 | Jun 2, 2010 | clinicaltrials |
| NCT00181558 | Atrasentan and Zometa for Men With Prostate Cancer Metastatic to Bone | completed | Phase 2 | 44 | Massachusetts General HospitalOTHER | 1 | May 10, 2010 | clinicaltrials |
| NCT00258765 | Adjuvant Docetaxel-Zoledronic Acid in High-risk Early Prostate Cancer Following Prostatectomy. | terminated | Phase 2 | 1 | Novartis PharmaceuticalsINDUSTRY | 1 | Apr 26, 2010 | clinicaltrials |
| NCT00557037 | A Phase II Trial of Phenoxodiol in Patients With Castrate and Non-Castrate Prostate Cancer | completed | Phase 2 | 60 | MEI Pharma, Inc.INDUSTRY | 1 | Apr 8, 2010 | clinicaltrials |
| NCT00003307 | Radiation Therapy Plus Amifostine in Treating Patients With Primary Prostate Cancer | completed | Phase 2 | 25 | University of ArizonaOTHER | 1 | Mar 16, 2010 | clinicaltrials |
| NCT01086683 | Rehabilitation of Cancer Survivors in Denmark: The Effect of a Psychosocial Rehabilitation Course | completed | Phase 2 / Phase 3 | 513 | Danish Cancer SocietyOTHER | 1 | Mar 15, 2010 | clinicaltrials |
| NCT00084526 | Computed Tomography (CT) Scans Using CT-On-Rails™ to Pinpoint the Location of the Tumor in Treating Patients With Prostate Cancer | completed | Phase 1 / Phase 2 | 40 | Fox Chase Cancer CenterOTHER | 1 | Feb 12, 2010 | clinicaltrials |
| NCT00166478 | Exisulind Prior to Radical Prostatectomy | completed | Phase 2 | 130 | Mayo ClinicOTHER | 1 | Jan 28, 2010 | clinicaltrials |
| NCT00176527 | Isotretinoin, Interferon Alfa-2b, Docetaxel, and Estramustine in Treating Patients With Metastatic Prostate Cancer That Did Not Respond to Hormone Therapy | terminated | Phase 2 | 40 | University of Medicine and Dentistry of New JerseyOTHER | 1 | Dec 11, 2009 | clinicaltrials |
| NCT00134706 | A Study of Docetaxel Plus Carboplatin in Patients With Hormone Refractory Prostate Cancer | completed | Phase 2 | 30 | Dana-Farber Cancer InstituteOTHER | 1 | Dec 9, 2009 | clinicaltrials |
| NCT00136487 | Celecoxib (Celebrex) Versus Placebo in Men With Recurrent Prostate Cancer | completed | Phase 2 / Phase 3 | 85 | Dana-Farber Cancer InstituteOTHER | 1 | Dec 9, 2009 | clinicaltrials |
| NCT00140478 | Mifepristone (RU-486) in Androgen Independent Prostate Cancer | completed | Phase 2 | 48 | Dana-Farber Cancer InstituteOTHER | 1 | Dec 9, 2009 | clinicaltrials |
| NCT00268710 | Docetaxel in Hormone Refractory Prostate Cancer (HRPC)[Weekly or 3weekly TAX + Prednisone in HRPC] | completed | Phase 2 | — | SanofiINDUSTRY | 0 | Dec 7, 2009 | clinicaltrials |
| NCT00166725 | Effects of Octreotide Acetate on Circulating Levels of Chromogranin A in Advanced Prostate Cancer Patients | completed | Phase 2 | 40 | NovartisINDUSTRY | 1 | Nov 19, 2009 | clinicaltrials |
| NCT00166426 | Exisulind Versus Placebo After Surgical Removal of the Prostate | completed | Phase 2 | 240 | Mayo ClinicOTHER | 1 | Nov 16, 2009 | clinicaltrials |
| NCT00541281 | Safety and Efficacy Study of of Docetaxel vs Docetaxel Estramustine in Hormone Refractory Prostatic Cancer | completed | Phase 2 | 150 | Cliniques universitaires Saint-Luc- Université Catholique de LouvainOTHER | 2 | Oct 27, 2009 | clinicaltrials |
| NCT00494338 | Phase II Trial of Docetaxel and Celecoxib in Patients With Androgen Independent Prostate Cancer | terminated | Phase 2 | 6 | SanofiINDUSTRY | 1 | Oct 1, 2009 | clinicaltrials |
| NCT00152789 | Normal Prostate: Oxygenation of the Prostate Gland in Men Undergoing Prostate Biopsy | completed | Phase 2 | 40 | University Health Network, TorontoOTHER | 1 | Aug 10, 2009 | clinicaltrials |
| NCT00230386 | Role of Magnetic Resonance Imaging (MRI) Perfusion to Detect Disease in Prostate Carcinoma | completed | Phase 1 / Phase 2 | 50 | University Health Network, TorontoOTHER | 1 | Jul 14, 2009 | clinicaltrials |
| NCT00895466 | Efficacy and Safety Study of the Therapeutic Vaccine PEP223 in Prostate Cancer Patients | unknown | Phase 1 / Phase 2 | 12 | Pepscan TherapeuticsINDUSTRY | 1 | May 8, 2009 | clinicaltrials |
| NCT00241475 | Gefitinib in the Treatment of the First Relapse of Prostate Cancer Beyond Prostatectomy or Radiotherapy | completed | Phase 2 | 30 | AstraZenecaINDUSTRY | 1 | Apr 23, 2009 | clinicaltrials |
| NCT00635856 | Open Label Trial to Assess Iressa in Prostate Cancer Patients | completed | Phase 2 | 100 | AstraZenecaINDUSTRY | 0 | Apr 23, 2009 | clinicaltrials |
| NCT00291005 | PhII One Label Non-Comparative Trial in Metastatic Hormone Refractory Prostate Cancer in Combination With Prednisolone | completed | Phase 2 | 42 | SanofiINDUSTRY | 1 | Mar 27, 2009 | clinicaltrials |
| NCT00043576 | ASCENT: Androgen Independent Prostate Cancer Study of Calcitriol Enhancing Taxotere | unknown | Phase 2 / Phase 3 | 250 | NovaceaINDUSTRY | 2 | Mar 12, 2009 | clinicaltrials |
| NCT00200824 | Effects of Soy Compounds on Breast Cancer, Prostate Cancer, and Bone Health | completed | Phase 2 | — | National Center for Complementary and Integrative Health (NCCIH)NIH | 1 | Mar 12, 2009 | clinicaltrials |
| NCT00619996 | Study of Sorafenib and Docetaxel in Metastatic Prostate Cancer(P1) | completed | Phase 2 | 43 | Italian Trial in Medical OncologyOTHER | 1 | Feb 26, 2009 | clinicaltrials |
| NCT00122005 | GVAX in Advanced Prostate Cancer Patients Made Lymphopenic | unknown | Phase 1 / Phase 2 | 18 | Providence Health & ServicesOTHER | 1 | Feb 24, 2009 | clinicaltrials |
| NCT00111618 | Study of AS1404 With Docetaxel in Patients With Hormone Refractory Metastatic Prostate Cancer | completed | Phase 2 | 70 | Antisoma ResearchINDUSTRY | 1 | Jan 30, 2009 | clinicaltrials |
| NCT00018538 | Calcifidol Therapy in Men With Cancer | completed | Phase 2 | — | US Department of Veterans AffairsFED | 1 | Jan 21, 2009 | clinicaltrials |
| NCT00657982 | Phase II Study of RAD001 in a Neoadjuvant Setting in Men With Intermediate or High Risk Prostate Cancer | unknown | Phase 2 | 15 | Sheba Medical CenterOTHER_GOV | 1 | Jan 21, 2009 | clinicaltrials |
| NCT00167648 | Neoadjuvant Estradiol or Androgen Deprivation in Clinically Localized Prostate Cancer(NE2) | completed | Phase 2 | 17 | University of WashingtonOTHER | 1 | Jan 19, 2009 | clinicaltrials |
| NCT00174863 | Evaluation of SR 31747A Versus Placebo in Androgen-Independent Non Metastatic Prostate Cancer(ODYSSEY) | completed | Phase 2 | 232 | SanofiINDUSTRY | 13 | Dec 23, 2008 | clinicaltrials |
| NCT00127465 | Investigating the Impact of Tailored Reports on Anxiety Amongst Cancer Patients and Their Confidants | completed | Phase 1 / Phase 2 | 400 | University of PlymouthOTHER | 1 | Dec 11, 2008 | clinicaltrials |
| NCT00394810 | Efficacy and Pharmacodynamic Study of Panzem® NCD in Patients With Hormone-Refractory Prostate Cancer | completed | Phase 2 | 21 | CASI pharmaceuticals, Inc.INDUSTRY | 1 | Nov 25, 2008 | clinicaltrials |
| NCT00090376 | Evaluate the Effects of GPI 1485 on Erectile Function Following Bilateral Nerve-Sparing Prostatectomy | completed | Phase 2 | 240 | Eisai Inc.INDUSTRY | 1 | Nov 7, 2008 | clinicaltrials |
| NCT00546039 | Synthetic Genistein (BONISTEIN™) in Patients Who Are Undergoing Surgery for Prostate Cancer | unknown | Phase 2 | 47 | University Hospital, AkerOTHER | 1 | Sep 30, 2008 | clinicaltrials |
| NCT00104130 | Study of KOS-862 (Epothilone D) in Metastatic Prostate Cancer | terminated | Phase 2 | 53 | Bristol-Myers SquibbINDUSTRY | 1 | Sep 17, 2008 | clinicaltrials |
| NCT00425204 | Study for Patients Who Have Benefited and Tolerated Prior Panitumumab Treatment | completed | Phase 2 | 31 | AmgenINDUSTRY | 0 | Sep 15, 2008 | clinicaltrials |
| NCT00024414 | DHA-Paclitaxel in Treating Patients With Metastatic Prostate Cancer | unknown | Phase 2 | — | TheradexINDUSTRY | 1 | Jul 24, 2008 | clinicaltrials |
| NCT00087854 | Study of Individualized Amonafide to Treat Prostate Cancer | completed | Phase 1 / Phase 2 | 40 | Xanthus Pharmaceuticals, Inc.INDUSTRY | 1 | Apr 23, 2008 | clinicaltrials |
| NCT00108290 | Chemotherapy, Hormone Therapy, and Surgery to Remove the Prostate Gland in Patients With High Risk Prostate Cancer | completed | Phase 2 | — | US Department of Veterans AffairsFED | 1 | Apr 4, 2008 | clinicaltrials |
| NCT00001266 | A Phase II Trial of Leuprolide + Flutamide + Suramin in Untreated Poor Prognosis Prostate Carcinoma | completed | Phase 2 | 70 | National Cancer Institute (NCI)NIH | 1 | Mar 4, 2008 | clinicaltrials |
| NCT00001446 | A Randomized Phase II Study of Oral Thalidomide in Patients With Hormone-Refractory Prostate Cancer | completed | Phase 2 | 64 | National Cancer Institute (NCI)NIH | 1 | Mar 4, 2008 | clinicaltrials |
| NCT00278070 | Metronomic Oral Vinorelbine in Patients With Metastatic Tumors | completed | Phase 2 | — | Hellenic Cooperative Oncology GroupOTHER | 1 | Feb 29, 2008 | clinicaltrials |
| NCT00064610 | Phase I/II Dose Escalation Study of VELCADE® and Docetaxel in Patients With Advanced Androgen-Independent Prostate Cancer | completed | Phase 1 / Phase 2 | 102 | Millennium Pharmaceuticals, Inc.INDUSTRY | 1 | Feb 11, 2008 | clinicaltrials |
Data updated 23 days agoSource updated Aug 5, 2010source: clinicaltrials